A possible case of etoricoxib induced fixed drug eruption


  • Apoorva . Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
  • Girish K. Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
  • Namrata C. Manjunath Department of Dermatology and Venereology and Leprosy, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India




Adverse drug reaction, Etoricoxib, Fixed drug eruptions, NSAIDs


Fixed drug eruption (FDE) is a most commonly with adverse drug reaction seen with use of Non-steroidalanti-inflammatory drugs (NSAIDs) in particular nimesulide followed by antibiotics and anticonvulsants. Etoricoxib is a selective cyclo-oxygenase isoenzyme-2 inhibitor which is superior to conventional NSAIDs and causes less side effects. Authors present a case of fixed drug eruption due to etoricoxib in a male patient. A 50-year-old patient presented to Outpatient Department (OPD) of Dermatology of a Tertiary Care Hospital with complains of skin rashes over lips, oral cavity, trunk, both the upper and lower limbs, palm, soles, scrotum and glans penis since a week. The detailed history of the patient revealed the use of etoricoxib a week back, prescribed for low back pain. It was suspected that the cutaneous drug reaction was due to the use of etoricoxib. The suspected drug etoricoxib was stopped, patient was admitted and managed symptomatically. The above reaction was assessed to be “possible” as per WHO-UMC and Naranjo causality scale, “moderate” on Hartwig’s scale and “Probably preventable” according to Schumock and Thornton criteria. This case reporting was done to sensitize the prescribers regarding rare side effects of the above drug and the need to confirm past history of drug reaction before prescription.


Kumar P. Etoricoxib-induced pretibial erythema and edema. Indian Dermatol Online J. 2015 Dec;6(Suppl 1):S47.

Antunes J, Prates S, Leiria-Pinto P. Fixed drug eruption due to etoricoxibe-A case report. Allergol Immunopathol (Madr). 2013.

Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010 Jul 1;20(4):461-4.

Lee AY. Fixed drug eruptions. ixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol. 2000 Sep-Oct;1(5):277-85.

Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009 Aug 1;9(4):316-21.

Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions–a 20‐year review. Contact Dermatitis. 2011 Oct;65(4):195-201.

Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983 Jun 14;74(6):102-9.

Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheumatic Dis. 2007 Jul 1;66(7):945-51.

Mäkelä L, Lammintausta K. Etoricoxib-induced acute generalized exanthematous pustulosis. Acta dermato-venereologica. 2008 Jan 1;88(2):200-1.

Zaki S. Adverse drug reaction and causality assessment scales. Lung India. 2011 Apr 1;28(2):152.




How to Cite

., A., K., G., & Manjunath, N. C. (2019). A possible case of etoricoxib induced fixed drug eruption. International Journal of Basic & Clinical Pharmacology, 8(2), 343–345. https://doi.org/10.18203/2319-2003.ijbcp20190158



Case Reports